MCID: THY030
MIFTS: 53

Thyroid Gland Disease

Categories: Endocrine diseases

Aliases & Classifications for Thyroid Gland Disease

MalaCards integrated aliases for Thyroid Gland Disease:

Name: Thyroid Gland Disease 12 15
Abnormality of the Thyroid Gland 29 6
Thyroid Diseases 44 72

Classifications:



External Ids:

Disease Ontology 12 DOID:50
MeSH 44 D013959
NCIt 50 C26893
SNOMED-CT 68 14304000
ICD10 33 E00-E07 E07.9
UMLS 72 C0040128

Summaries for Thyroid Gland Disease

Disease Ontology : 12 An endocrine system disease that is located in the thyroid.

MalaCards based summary : Thyroid Gland Disease, also known as abnormality of the thyroid gland, is related to graves disease 1 and hyperthyroidism. An important gene associated with Thyroid Gland Disease is TG (Thyroglobulin), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Human Thyroid Stimulating Hormone (TSH) signaling pathway. The drugs Triamcinolone and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, testes and lymph node, and related phenotypes are endocrine/exocrine gland and limbs/digits/tail

Related Diseases for Thyroid Gland Disease

Diseases related to Thyroid Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 622)
# Related Disease Score Top Affiliating Genes
1 graves disease 1 32.9 TSHR TRH TPO THRB TG SERPINA7
2 hyperthyroidism 32.9 TSHR TRH TPO THRB TG SERPINA7
3 hyperthyroxinemia 32.8 TSHR TRH TPO SERPINA7
4 goiter 32.1 TSHR TRH TPO THRB TG SLC5A5
5 hypothyroidism 31.7 TSHR TSHB TRH TPO THRB TG
6 myxedema 31.6 TSHR TPO TG
7 subacute thyroiditis 31.5 TSHR TPO TG SERPINA7
8 multinodular goiter 31.4 TSHR TPO TG PAX8 NKX2-1 CALCA
9 graves' disease 31.2 TSHR TPO TG SERPINA7
10 thyroid carcinoma, familial medullary 31.1 TG RET NKX2-1 CALCA
11 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 TSHR TPO TG
12 acute thyroiditis 30.9 TG CALCA
13 thyroid crisis 30.9 THRB TG SERPINA7
14 postsurgical hypothyroidism 30.7 TSHR TRH TG
15 toxic diffuse goiter 30.7 TSHR TRH TPO TG SERPINA7
16 plummer's disease 30.7 TPO THRB TG
17 thyroid cancer, nonmedullary, 1 30.7 NKX2-1 NCOA4 MIR222 MIR221 MIR146B MIR146A
18 congenital hypothyroidism 30.7 TSHR TSHB TPO TG SLC5A5 SERPINA7
19 pendred syndrome 30.6 TPO TG PAX8
20 thyroid hormone resistance, generalized, autosomal dominant 30.6 TRH THRB TG SERPINA7
21 hashimoto thyroiditis 30.6 TSHR TSHB TPO TG RET CALCA
22 differentiated thyroid carcinoma 30.6 TSHR TPO TG RET PAX8 NKX2-1
23 papillary thyroid microcarcinoma 30.6 TSHR TG NKX2-1 CALCA
24 neonatal thyrotoxicosis 30.6 TSHR PAX8
25 nodular goiter 30.5 TSHR TPO TG SLC5A5 RET CALCA
26 hypothyroidism, congenital, nongoitrous, 2 30.5 TSHR TG SERPINA7 PAX8 NKX2-1
27 nontoxic goiter 30.5 TSHR TPO TG SERPINA7 CALCA
28 hashimoto encephalopathy 30.5 TSHR TPO
29 thyroiditis 30.5 TSHR TSHB TRH TPO THRB TG
30 follicular adenoma 30.5 TSHR TPO TG RET PAX8 NKX2-1
31 suppurative thyroiditis 30.5 TG CALCA
32 endemic goiter 30.4 TSHR TSHB TPO TG SERPINA7
33 familial thyroid dyshormonogenesis 30.4 TPO TG SLC5A5
34 generalized resistance to thyroid hormone 30.4 TRH THRB
35 fetal adenoma 30.4 TG NKX2-1 CALCA
36 hypothyroidism, congenital, nongoitrous, 4 30.2 TSHB TRH TPO TG SERPINA7
37 dermatomyositis 30.2 MIR222 MIR221 MIR146B
38 papillary carcinoma 30.2 TSHR TPO TG RET PAX8 NKX2-1
39 hypoadrenalism 30.0 TG CALCA
40 thyroid cancer, nonmedullary, 2 30.0 TSHR TPO THRB TG RET PAX8
41 autoimmune thyroid disease 3 12.6
42 autoimmune thyroid disease 1 12.3
43 autoimmune thyroid disease 2 12.3
44 autoimmune thyroid disease 4 12.3
45 igg4-related thyroid disease 12.2
46 rare genetic thyroid disease 12.1
47 rare thyroid disease 12.1
48 autoimmune polyendocrine syndrome, type ii 11.8
49 vitiligo-associated multiple autoimmune disease susceptibility 1 11.5
50 cholangitis, primary sclerosing 11.4

Comorbidity relations with Thyroid Gland Disease via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism

Graphical network of the top 20 diseases related to Thyroid Gland Disease:



Diseases related to Thyroid Gland Disease

Symptoms & Phenotypes for Thyroid Gland Disease

MGI Mouse Phenotypes related to Thyroid Gland Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.85 NKX2-1 PAX8 PTCH1 RET SLC5A5 TG
2 limbs/digits/tail MP:0005371 9.5 PAX8 PTCH1 RET TG THRB TPO
3 no phenotypic analysis MP:0003012 9.17 NKX2-1 PAX8 PTCH1 RET THRB TPCN1

Drugs & Therapeutics for Thyroid Gland Disease

Drugs for Thyroid Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 387)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
6
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
8
Acetaminophen Approved Phase 4 103-90-2 1983
9
Codeine Approved, Illicit Phase 4 76-57-3 5284371
10
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
11
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
14
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
15
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
16
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
17
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
18
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
19 Tranquilizing Agents Phase 4
20 Central Nervous System Depressants Phase 4
21 Psychotropic Drugs Phase 4
22 Antimetabolites Phase 4
23 Lipid Regulating Agents Phase 4
24 Hypolipidemic Agents Phase 4
25 Technetium Tc 99m Medronate Phase 4
26 triamcinolone acetonide Phase 4
27 Triamcinolone hexacetonide Phase 4
28 Triamcinolone diacetate Phase 4
29 Dopamine Agents Phase 4
30 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
31 Anticholesteremic Agents Phase 4
32 Cathartics Phase 4
33 Carboxymethylcellulose Sodium Phase 4
34 Laxatives Phase 4
35 Serotonin Agents Phase 4
36 Serotonin Antagonists Phase 4
37 Antipsychotic Agents Phase 4
38 Dopamine Antagonists Phase 4
39 Red yeast rice Phase 4
40 Red Yeast Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 policosanol Phase 4
43 Anesthetics Phase 4
44 Anesthetics, Local Phase 4
45 Hypnotics and Sedatives Phase 4
46 Narcotics Phase 4
47 Respiratory System Agents Phase 4
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
49 Analgesics, Opioid Phase 4
50 Antipyretics Phase 4

Interventional clinical trials:

(show top 50) (show all 613)
# Name Status NCT ID Phase Drugs
1 Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial Unknown status NCT00385983 Phase 4
2 Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
3 Effects of Dexmedetomidine on Cough Response and Postoperative Recovery Quality in Patients Undergoing Thyroid Surgery With General anesthesia---a Randomized Control Double-Blind Clinical Trial Unknown status NCT02613806 Phase 4 Dexmeditomidine;normal saline
4 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
5 A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy. Completed NCT03948191 Phase 4 Methylprednisolone;99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
6 Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study Completed NCT00400465 Phase 4
7 Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer? Completed NCT00604318 Phase 4 rhTSH
8 Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results Completed NCT00858104 Phase 4
9 A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal Completed NCT00001730 Phase 4 Thyrogen
10 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
11 Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism Completed NCT02500342 Phase 4 Levothyroxine;Placebo
12 Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction: a Prospective Evaluation and Impact of Treatment Completed NCT02491008 Phase 4 Levothyroxine;Placebo
13 Impact of Thyroid Hormone Replacement on Cardiac Function: a Randomized Placebo-Controlled Trial in Older Adults With Subclinical Hypothyroidism Completed NCT02832960 Phase 4 Levothyroxine;Placebo
14 Impact of Thyroid Hormone Replacement on Progression of Atherosclerosis : a Randomized Placebo-Controlled Trial in Older Adults With Subclinical Hypothyroidism. Completed NCT02832934 Phase 4 Levothyroxine;Placebo
15 Risperidone Augmentation for Treatment-Resistant Aggression in ADHD Completed NCT00297739 Phase 4 Risperidone
16 Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study Completed NCT02078167 Phase 4
17 Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
18 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
19 Efficacy of Dexmedetomidine for Cough Suppression During Anesthetic Emergence in Patients Undergoing Thyroid Surgery: A Randomized, Double Blinded, Controlled Trial Recruiting NCT03312413 Phase 4 Dexmedetomidine Hydrochloride;Normal Saline;Dexmedetomidine Hydrochloride;Dexmedetomidine Hydrochloride
20 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
21 Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Recruiting NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
22 Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism Active, not recruiting NCT01848171 Phase 4 L-thyroxine
23 The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study Active, not recruiting NCT01831869 Phase 4 L-thyroxine
24 Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients Active, not recruiting NCT02946918 Phase 4 Levothyroxine
25 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
26 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Not yet recruiting NCT03969108 Phase 4 Indocyanine Green
27 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
28 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Withdrawn NCT01927406 Phase 4 Prostaglandin Analog;Timolol
29 Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy Unknown status NCT01551914 Phase 3
30 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
31 "ShearWave" Elastography Interest in the Management of Thyroid Nodules Completed NCT01335828 Phase 2, Phase 3
32 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study Completed NCT01616316 Phase 2, Phase 3
33 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
34 Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery Completed NCT01189292 Phase 3 Dexamethasone
35 Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues. Completed NCT02155049 Phase 3 bimatoprost 0.03%
36 Prospective, Randomized, Double Blind, Multicenter Study for Hyalobarrier ® to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG® After Thyroidectomy Completed NCT01696305 Phase 3
37 Impact and Cost Efficiency of Bilateral, Superficial Cervical Block in Thyroid Surgery Under General Anesthesia Completed NCT00472446 Phase 2, Phase 3 bilateral superficial cervical block;placebo bilateral superficial cervical block
38 A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer Completed NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
39 A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
40 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial Completed NCT00795782 Phase 3
41 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
42 Thyroid Nodules Treated With Percutaneous Radiofrequency Thermal Ablation: a Comparative Study Completed NCT01649206 Phase 3
43 Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses. Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
44 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
45 The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer Completed NCT00794053 Phase 3
46 A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen® Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
47 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer Completed NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib
48 Effectiveness of Salbutamol Administration by Nebulizer Versus Metered Dose Inhaler With Spacer in Acute Asthma in Children in Suez Canal University Hospital Emergency Department: A Randomized Control Trial Completed NCT03816267 Phase 3 Salbutamol
49 Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
50 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3

Search NIH Clinical Center for Thyroid Gland Disease

Cochrane evidence based reviews: thyroid diseases

Genetic Tests for Thyroid Gland Disease

Genetic tests related to Thyroid Gland Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Thyroid Gland 29

Anatomical Context for Thyroid Gland Disease

MalaCards organs/tissues related to Thyroid Gland Disease:

41
Thyroid, Testes, Lymph Node, Eye, Breast, T Cells, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Thyroid Gland Disease:

19
Thyroid

Publications for Thyroid Gland Disease

Articles related to Thyroid Gland Disease:

(show top 50) (show all 4608)
# Title Authors PMID Year
1
The Aging Thyroid: A Reappraisal Within the Geroscience Integrated Perspective. 38
31074798 2019
2
Clock gene PERIOD3 polymorphism is associated with susceptibility to Graves' disease but not to Hashimoto's thyroiditis. 38
31328557 2019
3
An evaluation score of the difficulty of thyroidectomy considering operating time and preservation of recurrent laryngeal nerve. 38
30443896 2019
4
Effects of thyroid diseases on pregnancy outcomes. 38
31410141 2019
5
Abnormal Iodine Nutrition-Induced ER Stress Upregulates MCP-1 Expression Through P38/MAPK Signaling Pathway in Thyroid Cells. 38
30539387 2019
6
Comprehensive research on thyroid diseases associated with autoimmunity: autoimmune thyroid diseases, thyroid diseases during immune-checkpoint inhibitors therapy, and immunoglobulin-G4-associated thyroid diseases. 38
31434818 2019
7
Chronological association between alopecia areata and autoimmune thyroid diseases: A systematic review and meta-analysis. 38
31197884 2019
8
Monitoring of Thyroid Malfunction and Therapies in Pregnancy and the Postpartum Period: A Systematic Up-Dated Critical Review of the Literature. 38
31425445 2019
9
Oxidative damage to membrane lipids in the thyroid - no differences between sexes. 38
31373249 2019
10
Pharmacological exposures may precipitate craniosynostosis through targeted stem cell depletion. 38
31415959 2019
11
Deiodinases and their intricate role in thyroid hormone homeostasis. 38
31160732 2019
12
The Role of Vitamin D Receptor Gene Polymorphisms in Thyroid-Associated Orbitopathy. 38
31424978 2019
13
Bone of Contention: Helicobacter pylori and Osteoporosis-Is There an Association? 38
31407131 2019
14
EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. 38
31392371 2019
15
l-Thyroxine does not prevent immunemediated sensorineural hearing loss in autoimmune thyroid diseases. 38
30107874 2019
16
Evaluation of trace metals in thyroid tissues: Comparative analysis with benign and malignant thyroid diseases. 38
31365889 2019
17
Hypoparathyroidism After Total Thyroidectomy: Importance of the Intraoperative Management of the Parathyroid Glands. 38
30919027 2019
18
The MAGI2 gene polymorphism rs2160322 is associated with Graves' disease but not with Hashimoto's thyroiditis. 38
30535759 2019
19
Association between lifestyle and thyroid dysfunction: a cross-sectional epidemiologic study in the She ethnic minority group of Fujian Province in China. 38
31362731 2019
20
Oral lichen planus and thyroid gland diseases: possible associations. 38
31366342 2019
21
Association of IFNG gene methylation in peripheral blood cells with the development and prognosis of autoimmune thyroid diseases. 38
31279175 2019
22
Editorial commentary: Amiodarone-induced thyroid diseases: Additional unintended consequences. 38
31130186 2019
23
Type 1 diabetes mellitus and thyroid diseases: relationship between glycometabolism and thyroid function. 38
31286754 2019
24
Thyroid disease and the metabolic syndrome. 38
31369412 2019
25
50 years of the ETA: "the selenium connection". 38
31364024 2019
26
Genome-wide meta-analysis identifies novel gender specific loci associated with thyroid antibodies level in Croatians. 38
29678681 2019
27
Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study. 38
31319795 2019
28
Identification and Application of an Aptamer Targeting Papillary Thyroid Carcinoma Using Tissue-SELEX. 38
31141341 2019
29
Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and thyroid diseases. 38
30794525 2019
30
Vitiligo and Hashimoto's thyroiditis: Autoimmune diseases linked by clinical presentation, biochemical commonality, and autoimmune/oxidative stress-mediated toxicity pathogenesis. 38
31203913 2019
31
Investigation of blood groups in benign thyroid diseases in Turkey. 38
31308303 2019
32
Promoter methylation and expression of intercellular adhesion molecule 1 gene in blood of autoimmune thyroiditis patients. 38
31359380 2019
33
Association of benign thyroid diseases with thyroid cancer risk: a meta-analysis of prospective observational studies. 38
30387079 2019
34
Autoimmune and non-autoimmune thyroid dysfunction in HCV infected and HCV-HIV co-infected patients before and after interferon alpha therapy: A prospective study. 38
31266712 2019
35
Circulating adipokines and metabolic setting in differentiated thyroid cancer. 38
31252407 2019
36
An underestimated comorbidity of COPD: Thyroid dysfunction. 38
31414644 2019
37
Natural Killer Cells and Thyroid Diseases. 38
31257741 2019
38
Genetics of Thyroid Disorders. 38
31301652 2019
39
Total circulating cell-free miRNA in plasma as a predictive biomarker of the thyroid diseases. 38
30506793 2019
40
Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. 38
30868219 2019
41
Risk Factors for Dry Eye in Mainland China: A Multi-Center Cross-Sectional Hospital-Based Study. 38
31218906 2019
42
Reference intervals for thyroid-stimulating hormone, free thyroxine, and free triiodothyronine in elderly Chinese persons. 38
30496133 2019
43
Thyroid hemiagenesis is combined with a variety of thyroid disorders. 38
30974469 2019
44
Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. 38
31182340 2019
45
The association between thyroid hormone balance and thyroid volume in patients with Hashimoto thyroiditis. 38
31155540 2019
46
Systemic lupus erythematosus and thyroid disease - Experience in a single medical center in Taiwan. 38
28712818 2019
47
Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case-control study in an Italian cohort. 38
30406929 2019
48
Overtime trend of thyroid hormones and thyroid autoimmunity and ovarian reserve: a longitudinal population study with a 12-year follow up. 38
31064360 2019
49
Genome-wide association analysis suggests novel loci for Hashimoto's thyroiditis. 38
30284222 2019
50
The technique of story-telling in thyroid diseases including surgery; useful or not. 38
31016018 2019

Variations for Thyroid Gland Disease

ClinVar genetic disease variations for Thyroid Gland Disease:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 COL7A1 NM_000094.3(COL7A1): c.1442G> A (p.Arg481His) single nucleotide variant Likely pathogenic rs147040026 3:48629171-48629171 3:48591738-48591738

Expression for Thyroid Gland Disease

Search GEO for disease gene expression data for Thyroid Gland Disease.

Pathways for Thyroid Gland Disease

GO Terms for Thyroid Gland Disease

Cellular components related to Thyroid Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 TSHB TPO SERPINA7 MIR222 MIR221 MIR146A

Biological processes related to Thyroid Gland Disease according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.98 RET PTCH1 PAX8 NKX2-1 NCOA4
2 gene silencing by miRNA GO:0035195 9.97 MIR222 MIR221 MIR146B MIR146A MIR144
3 cell-cell signaling GO:0007267 9.85 TSHR TSHB TRH CALCA
4 animal organ morphogenesis GO:0009887 9.77 THRB PTCH1 NKX2-1
5 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.65 MIR221 MIR146B MIR146A
6 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.59 MIR222 MIR221
7 thyroid hormone generation GO:0006590 9.57 TPO SLC5A5
8 hormone biosynthetic process GO:0042446 9.56 TPO TG
9 cellular response to gonadotropin stimulus GO:0071371 9.54 SLC5A5 PAX8
10 positive regulation of axon regeneration GO:0048680 9.52 MIR222 MIR221
11 negative regulation by host of viral genome replication GO:0044828 9.51 MIR222 MIR221
12 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.49 MIR222 MIR221
13 negative regulation of cell adhesion molecule production GO:0060354 9.46 MIR222 MIR221
14 iodide transport GO:0015705 9.43 TG SLC5A5
15 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.4 MIR222 MIR221
16 thyroid-stimulating hormone signaling pathway GO:0038194 9.37 TSHR PAX8
17 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.32 MIR222 MIR221
18 response to pain GO:0048265 9.3 RET
19 positive regulation of Schwann cell migration GO:1900149 9.26 MIR222 MIR221
20 hormone-mediated signaling pathway GO:0009755 9.26 TSHR TSHB TRH THRB
21 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.16 MIR222 MIR221
22 thyroid gland development GO:0030878 8.92 THRB TG PAX8 NKX2-1

Molecular functions related to Thyroid Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.46 TSHB TRH TG CALCA
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR222 MIR221 MIR146B MIR146A MIR144
3 thyroid-stimulating hormone receptor activity GO:0004996 8.96 TSHR PAX8

Sources for Thyroid Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....